Apyx Medical Corp

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apyx Medical Corp reports Q4 revenue decline, eyes 2023 growth

Apyx Medical Corp faced revenue challenges in Q4 2022, but secured new clearances and credit facilities.
The company anticipates improved revenue and profitability in 2023 with strategic initiatives.
Despite losses and reduced cash reserves, Apyx aims to enhance product offerings and financial stability.
Management's actions aim to address concerns and position the company for growth in 2023.

Apyx Medical Corp reports Q1 revenue beat but faces cost challenges

Apyx Medical Corp faced mixed results in Q1 2023 with revenue exceeding expectations but a decline in gross profit and net loss.
The company showcased strengths in OEM sales, product launches, and property transactions, while grappling with challenges in certain sales segments.
With revised revenue guidance, margin expectations, and growth opportunities, Apyx has a strategic roadmap for future performance improvements.

Apyx Medical Corp reports strong Q2 growth and reaffirms 2023 guidance

Apyx Medical Corp demonstrated robust growth in Q2 2023, driven by Advanced Energy product sales and operational efficiency improvements.
While facing challenges in certain regions and managing operating expenses, the company's strategic initiatives and revenue diversification are key strengths.
With reaffirmed financial guidance and opportunities for market expansion, Apyx is poised for continued growth and innovation in the medical device industry.

Apyx Medical Corp reports robust Q3 performance and strategic initiatives

Apyx Medical Corp's Q3 2023 earnings call showcased strong revenue growth, improved gross profit margins, and strategic initiatives to address challenges. With a focus on operational efficiency and new product introductions, the company aims to drive future growth and profitability.

Apyx Medical Corp reports strong Q4 revenue growth and eyes market expansion

Apyx Medical Corp delivered strong revenue growth in Q4 2023 driven by Advanced Energy products and international sales performance.
While facing challenges in net loss and operating expenses, the company's technology and clinical support remain key strengths.
Opportunities lie in financial growth targets, market recognition, and leveraging positive feedback to drive future success.
Overall, Apyx Medical Corp's performance reflects resilience and potential for growth in the medical technology sector.

Apyx Medical Corp reports Q1 revenue decline, focuses on cost control

Apyx Medical Corp faced revenue decline in Q1 2024, driven by lower Advanced Energy sales.
The company showcased strengths in cost control, operational achievements, and revenue diversification.
Challenges include declining Advanced Energy sales and a projected net loss for 2024.
Opportunities lie in driving Renuvion technology adoption and addressing segment sales challenges.

Apyx Medical Corp reports Q3 revenue decline, bets on Ayon

Apyx Medical Corp's Q3 2024 performance reflects a mixed financial picture with revenue decline but promising growth in key segments like disposable handpieces.
Management's strategic initiatives, including the Ayon system launch and cost-saving measures, aim to drive future growth and achieve cash flow breakeven by 2027.
While facing revenue challenges and financial losses, the company's focus on operational efficiency and product innovation presents opportunities for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Apyx Medical (NASDAQ:APYX) decreased 2.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 75.00% year over year to ($0.04), which beat the estimate of ($0.11).

Apyx Medical: Q4 Earnings Insights

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its fourth quarter and full year ended December 31, 2020, and introduced financial expectations for the full year ending December 31, 2021. Fourth Quarter 2020 Financial Summa

Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook

Apyx Medical (NASDAQ:APYX) announces its next round of earnings this Wednesday, March 31. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

Apyx Medical's Earnings: A Preview

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Apyx (APYX) Upgraded to Buy: What Does It Mean for the Stock?

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the fourth quarter and fiscal year 2020 will be released before the market opens on Wednesday, March 31. Management will host a conference call at 8:00 a.m. Eastern Time

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2020 Financial Results on March 31, 2021

As of late, it has definitely been a great time to be an investor in Apyx Medical (APYX).

Apyx Medical's (APYX) Shares March Higher, Can It Continue?

Does Apyx Medical (APYX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love Apyx Medical (APYX)

Apyx (APYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Apyx (APYX) Upgraded to Buy: Here's Why

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2020. Preliminary Fourth Quarter 2020 Revenue Summary: Total Q4 revenue in a range of approximately $10.9 to $11.

Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2020 Revenue Results

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the ICR Conference 2021, which is being held virtually from January 11th-14th. Management will participate in a fireside chat on Thursday, January 14th at 9:15

Apyx Medical Corporation to Participate in the ICR Conference 2021

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it received approval from the FDA to begin Phase II of its U.S. IDE clinical study evaluating the use of its Renuvion® technology in skin laxity procedures in the neck and submental region. “We ar

Apyx Medical Corporation Announces Approval from FDA to Begin Phase II of U.S. IDE Study

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q3 2020 Results - Earnings Call Transcript

Apyx (APYX) delivered earnings and revenue surprises of 18.75% and 3.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Apyx Medical (APYX) Reports Q3 Loss, Tops Revenue Estimates

Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q3 results.

Recap: Apyx Medical Q3 Earnings

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its third quarter ended September 30, 2020. Third Quarter 2020 Financial Summary: Total revenue of $7.0 million, down 8.2% year-over-year. Advanced Energy revenue of $5.5 mill

Apyx Medical Corporation Reports Third Quarter 2020 Financial Results

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that it has completed subject enrollment in a U.S. Investigational Device Exemption (IDE) clinical study evaluating the use of its Renuvion® Technology in dermal resurfacing procedures. The Compan

Apyx Medical Corporation Announces Updates on U.S. IDE Clinical Studies

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced the publication of two separate peer-reviewed articles published in the journal, Dermatological Reviews. “We are very pleased to announce these two peer-reviewed clinical publications, which repre

Apyx Medical Corporation Announces Two Peer-Reviewed Clinical Publications Evaluating Renuvion's Helium Plasma Technology

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the third quarter of fiscal year 2020 will be released before the market opens on Monday, November 9. Management will host a conference call at 8:00 a.m. Eastern Time on

Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2020 Financial Results on November 9, 2020

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences: The 2020 Colliers Institutional Investor Conference Management will participate in virtual 1x1 meetings on Thursday

Apyx Medical Corporation to Participate in Upcoming Investor Conferences in September

Apyx Medical Corporation (APYX) CEO Charlie Goodwin on Q2 2020 Results - Earnings Call Transcript

Shares of Apyx Medical (NASDAQ:APYX) remained unaffected after the company reported Q2 results.

Recap: Apyx Medical Q2 Earnings

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its second quarter ended June 30, 2020.

Apyx Medical Corporation Reports Second Quarter 2020 Financial Results

NEW YORK, July 30, 2020 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, California and Georgia, announces an investigation of Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical Corp.," or the "Company").

WeissLaw LLP: Apyx Medical Corporation is the Subject of a Legal Investigation

CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that the Company has obtained regulatory approval to market and sell its Helium Plasma Technology products in five new countries: Australia, Brazil, Israel, Taiwan and Thailand. The Company has co

Apyx Medical Corporation Announces Regulatory Clearance to Market and Sell its Helium Plasma Technology Products in Five New Countries

PHILADELPHIA, June 6, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company's stockholders. In September 2019, a securities fraud complaint was filed against Apyx in federal court...

News for Apyx Medical Corp Stock (APYX)